

# ASX ANNOUNCEMENT

30 August 2021

## EXTENDED MANUFACTURING AGREEMENT FOR CARDIOCEL™ AND VASCUCEL™ SECURED WITH LEMAITRE

**Brisbane, Australia and Minneapolis, USA.** Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) is pleased to announce that it has signed a further agreement with LeMaitre Vascular Inc ("LeMaitre") to extend the Company's manufacturing of CardioCel™ and VasculCel™ at its Malaga facility in Western Australia.

The agreement includes a nine-month extension to the current manufacturing contract, which will now conclude in July 2023. Anteris will continue to receive existing agreed pricing over the extension period amended to remove the foreign exchange risk and continues to retain sole-control of the entire IP portfolio for ADAPT®, the tissue technology on which the Company's DurAVR™ single-piece 3D aortic valve is built, which is licensed to LeMaitre for specified fields of use.

The CardioCel™ product portfolio is the world's first 3D shaped and proven fully acellular collagen bio-scaffold. Both CardioCel™ and VasculCel™ were developed by leveraging the Company's anti-calcification ADAPT® tissue technology. CardioCel™ is designed for highly complex congenital defect repairs by enabling cardiac surgeons to achieve a more natural shape during aortic arch reconstruction.

This extended manufacturing agreement follows the sale of Anteris' CardioCel™ and VasculCel™ product range to LeMaitre in 2019 (ref. announcement 14 October 2019) and delivers the Company additional ongoing revenue from its internally developed proprietary products.

In addition, LeMaitre will assume the responsibility for applying for the regulatory approvals under European Medical Devices Directorate Regulation. The associated costs will also be assumed by LeMaitre and deducted from the \$AUD 3M earn-out and payable in instalments upon receipt of each product approval under European Medical Devices Directorate Regulation.

"This extension helps maximise the capacity utilization of our facility in Australia as we continue to manufacture our DurAVR™ valves alongside the CardioCel™ range. This additional extension will expire at the point where commercial production of DurAVR™ is increasing in scale," said Wayne Paterson, Chief Executive Officer of Anteris.

**ENDS**

**Anteris Technologies Ltd Registered Office:**

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

**Customer Service**

T +61 1300 550 310 | F +61 1300 972 437 | E [info@anteristech.com](mailto:info@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



### **Authorisation and Additional information**

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

### **For more information:**

Hannah Howlett

WE Communications

E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)

P: +61 4 5064 8064

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

### **About LeMaitre Vascular Inc. (NASDAQ: LMAT)**

LeMaitre Vascular Inc is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition affecting more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at [www.lemaitre.com](http://www.lemaitre.com).

### **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.